Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Shiro Takekawa"'
Autor:
Akiho Yoshida, Shinya Okamura, Shiho Torii, Sayuri Komatsu, Paola Miyazato, Hitomi Sasaki, Shiori Ueno, Hidehiko Suzuki, Wataru Kamitani, Chikako Ono, Yoshiharu Matsuura, Shiro Takekawa, Koichi Yamanishi, Hirotaka Ebina
Publikováno v:
iScience, Vol 25, Iss 11, Pp 105412- (2022)
Summary: Live-attenuated vaccines are generally highly effective. Here, we aimed to develop one against SARS-CoV-2, based on the identification of three types of temperature-sensitive (TS) strains with mutations in nonstructural proteins (nsp), impai
Externí odkaz:
https://doaj.org/article/9c93efb921c54f8ab1c3c64c204d905b
Autor:
Taisuke Mochida, Kazumi Take, Toshiyuki Maki, Masanori Nakakariya, Ryutaro Adachi, Kenjiro Sato, Tomoyuki Kitazaki, Shiro Takekawa
Publikováno v:
FEBS Open Bio, Vol 10, Iss 3, Pp 316-326 (2020)
Monoacylglycerol O‐acyltransferase 2 (MGAT2) is one of the key enzymes responsible for triglyceride (TG) re‐synthesis in the small intestine. We have previously demonstrated that pharmacological inhibition of MGAT2 has beneficial effects on obesi
Externí odkaz:
https://doaj.org/article/f71acd79c2a94847a9e05530ec3263c4
Autor:
Kazumi Take, Taisuke Mochida, Toshiyuki Maki, Yoshinori Satomi, Megumi Hirayama, Masanori Nakakariya, Nobuyuki Amano, Ryutaro Adachi, Kenjiro Sato, Tomoyuki Kitazaki, Shiro Takekawa
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150976 (2016)
Monoacylglycerol O-acyltransferase 2 (MGAT2) catalyzes the synthesis of diacylglycerol (DG), a triacylglycerol precursor and potential peripheral target for novel anti-obesity therapeutics. High-throughput screening identified lead compounds with MGA
Externí odkaz:
https://doaj.org/article/c8df05438cd04ac5a4bafa334ec8568d
Autor:
Ryutaro Adachi, Taisuke Mochida, Tomoyuki Kitazaki, Kazumi Take, Kenjiro Sato, Shiro Takekawa, Masanori Nakakariya, Toshiyuki Maki
Publikováno v:
FEBS Open Bio, Vol 10, Iss 3, Pp 316-326 (2020)
FEBS Open Bio
FEBS Open Bio
Monoacylglycerol O‐acyltransferase 2 (MGAT2) is one of the key enzymes responsible for triglyceride (TG) re‐synthesis in the small intestine. We have previously demonstrated that pharmacological inhibition of MGAT2 has beneficial effects on obesi
Autor:
Akiho Yoshida, Shinya Okamura, Shiho Torii, Sayuri Komatsu, Paola Miyazato, Shiori Ueno, Hidehiko Suzuki, Wataru Kamitani, Chikako Ono, Yoshiharu Matsuura, Shiro Takekawa, Koichi Yamanishi, Hirotaka Ebina
SUMMARYLive attenuated vaccines are generally highly effective. Here, we aimed to develop one against SARS-CoV-2, based on the identification of three types of temperature-sensitive (TS) strains with mutations in nonstructural proteins (nsp), impaire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31deaa59caa0199ee5a94a5631c0ee6
https://doi.org/10.1101/2021.02.15.430863
https://doi.org/10.1101/2021.02.15.430863
Autor:
Junichi Sakamoto, Kazue Tsuchimori, Yoshimasa Ishimura, Taiji Asami, Taisuke Mochida, Hideki Hirabayashi, Yoko Kanematsu-Yamaki, Tomoko Asakawa, Mariko Yoneyama-Hirozane, Yusuke Adachi, Naoki Nishizawa, Kouta Matsumiya, Hisashi Fujita, Hideo Fukui, Shiro Takekawa, Ayumu Niida
Publikováno v:
Bioorganic & Medicinal Chemistry. 26:566-572
Neuropeptide Y2 receptor (Y2R) agonism is an important anorectic signal and a target of antiobesity drug discovery. Recently, we synthesized a short-length Y2R agonist, PYY-1119 (4-imidazolecarbonyl-[ d -Hyp24,Iva25,Pya(4)26,Cha27,36,γMeLeu28,Lys30,
Autor:
Tomoko Asakawa, Kotaro Yokoyama, Junichi Sakamoto, Kouta Matsumiya, Hiroaki Nagai, Yoko Kanematsu-Yamaki, Shiro Takekawa, Taiji Asami, Jiro Noguchi, Hisashi Fujita, Hiroshi Inooka, Tomoko Kaisho, Kazue Tsuchimori, Katsuko Dote, Naoki Nishizawa, Tetsuya Ohtaki
Publikováno v:
British Journal of Pharmacology. 175:359-373
Background and Purpose Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effec
Autor:
Taiji Asami, Naoki Nishizawa, Hiroaki Nagai, Yoko Kanematsu-Yamaki, Ayako Shimizu, Shiro Takekawa, Hisashi Fujita, Masaaki Funata, Junichi Sakamoto
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:4626-4629
Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both recept
Autor:
Kotaro Yokoyama, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu-Yamaki, Tetsuya Ohtaki, Yasushi Masuda, Yoko Noguchi, Satoshi Kumano, Yusuke Adachi, Taiji Asami, Shiro Takekawa, Nobuyuki Amano, Tomoko Asakawa, Hideki Hirabayashi
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:5718-5725
Continuous administration of a 14-amino acid peptide YY (PYY) analog, Ac-[d-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys30]PYY(23-36) (4), which has a high binding affinity and agonist activity for the neuropeptide Y2 receptor (Y2R), has previously shown an
Autor:
Katsuko Dote, Naoki Nishizawa, Taiji Asami, Hiroshi Inooka, Hiroaki Nagai, Tomoko Asakawa, Hisashi Fujita, Yoko Kanematsu-Yamaki, Junichi Sakamoto, Taisuke Mochida, Hideki Hirabayashi, Kouta Matsumiya, Shiro Takekawa, Tetsuya Ohtaki, Tomoko Kaisho
Publikováno v:
Journal of Medicinal Chemistry. 60:6089-6097
Neuromedin U (NMU) is a neuropeptide that mediates a variety of physiological functions via its receptors, NMUR1 and NMUR2. Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. A short form of N